Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML

被引：0

作者：

Kuzmanovic, Teodora ^{[1
]}

Patel, Bhumika J. ^{[2
]}

Nagata, Yasunobu ^{[3
]}

Awada, Hassan ^{[4
]}

Hirsch, Cassandra M. ^{[3
]}

Przychodzen, Bartlomiej P. ^{[1
]}

Sanikommu, Srinivasa Reddy ^{[5
]}

Williams, Louis ^{[1
]}

Mukherjee, Sudipto ^{[2
]}

Advani, Anjali S. ^{[2
]}

Nazha, Aziz ^{[6
]}

Gerds, Aaron T. ^{[7
]}

Radivoyevitch, Tomas ^{[3
]}

Carraway, Hetty E. ^{[8
]}

Sekeres, Mikkael A. ^{[1
]}

Maciejewski, Jaroslaw P. ^{[3
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA

[2] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH 44106 USA

[3] Cleveland Clin Fdn, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, 9500 Euclid Ave, Cleveland, OH 44195 USA

[4] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Fairview Pk, OH USA

[5] Carolinas Healthcare Syst, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA

[6] Cleveland Clin, Cleveland, OH 44106 USA

[7] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[8] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-120059

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4353

引用

页数：4

共 50 条

[1] Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
Valk, Peter J. M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S3 - S5
[2] TP53 in MDS and AML: Biological and clinical advances
Zhao, Yeqian
Chen, Weihao
Yu, Jing
Pei, Shanshan
Zhang, Qiang
Shi, Jimin
Huang, He
Zhao, Yanmin
CANCER LETTERS, 2024, 588
[3] Comparison the Distinct Clinical Outcome with TP53 Mutation Status in MDS and AML :an Retrospective Study
Xiang, Xinrong
Ou, Yang
Wu, Yu
BLOOD, 2019, 134
[4] TP53 in AML and MDS: The new (old) kid on the block
Marks, Jennifer A.
Wang, Xin
Fenu, Elena M.
Bagg, Adam
Lai, Catherine
BLOOD REVIEWS, 2023, 60
[5] TP53 and the star-crossed lovers MDS and AML
Welch, John S.
BLOOD, 2022, 139 (15) : 2265 - 2266
[6] Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
Ozcan, Gonca
Popat, Uday R.
Kebriaei, Partow
Alousi, Amin M.
Alatrash, Gheath
Bashir, Qaiser
Mehta, Rohtesh S.
Ramdial, Jeremy L.
Rondon, Gabriela
Shpall, Elizabeth J.
Champlin, Richard E.
Oran, Betul
BLOOD, 2022, 140 : 10620 - 10621
[7] Allo-HSCT in Treatment of TP53 Mutation-Related MDS/AML in Pediatric Patients - Report of Two Cases
Deregowski, Maksymilian
Deregowska, Paulina
Sobkowiak-Sobierajska, Agnieszka
Wachowiak, Jacek
BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 321 - 322
[8] TP53 Mutation Characteristics and Their Effects on Overall Survival in AML and MDS
Puzo, Christian
Hager, Karl
Rinder, Henry
Weinberg, Olga
Siddon, Alexa
LABORATORY INVESTIGATION, 2024, 104 (03) : S1468 - S1470
[9] Treatment-related AML/MDS in multiple myeloma
Vadikoliou, C.
Lalayianni, C.
Papalexadri, A.
Neokleous, N.
Sakellari, I.
Athanasiadou, A.
Smias, C.
Fassas, A.
Anagnostopoulos, A.
LEUKEMIA RESEARCH, 2009, 33 : S101 - S101
[10] Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
Stengel, Anna
Meggendorfer, Manja
Walter, Wencke
Baer, Constance
Nadarajah, Niroshan
Hutter, Stephan
Kern, Wolfgang
Haferlach, Torsten
Haferlach, Claudia
BLOOD, 2022, 140 : 2073 - 2074

← 1 2 3 4 5 →